H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lu AF11167
Drug: Itraconazole

First Posted Date: 2014-07-24

Last Posted Date: 2015-09-21

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 20

Registration Number: NCT02199431

Locations: 🇬🇧
Covance, Leeds, United Kingdom

Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use

Phase 4

Completed

Conditions: Alcohol Dependence

Interventions: Drug: nalmefene

First Posted Date: 2014-07-22

Last Posted Date: 2016-12-14

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 45

Registration Number: NCT02197598

Locations: 🇩🇪
DE001, Heidelberg, Germany
🇩🇪
Optuminisight, München, Germany
🇩🇪
DE002, Mannheim, Germany

Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

Phase 4

Terminated

Conditions: Alcohol Dependence

First Posted Date: 2014-07-21

Last Posted Date: 2017-02-28

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 378

Registration Number: NCT02195817

Locations: 🇬🇧
GB003, Lanarkshire, United Kingdom
🇬🇧
GB006, Swansea, United Kingdom
🇫🇷
FR010, Becon-les-Granits, France

and more 45 locations

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Phase 3

Terminated

Conditions: Dravet Syndrome

Interventions: Drug: Clobazam

First Posted Date: 2014-07-11

Last Posted Date: 2017-03-27

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 3

Registration Number: NCT02187809

Locations: 🇺🇸
US010, Los Angeles, California, United States
🇺🇸
US003, Rochester, Minnesota, United States
🇺🇸
US0011, Dallas, Texas, United States

and more 6 locations

Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)

Phase 1

Completed

Conditions: Healthy Men and Women

Interventions: Drug: Flupentixol/melitracen coated tablet (Deanxit®)
Drug: Flupentixol/melitracen film-coated tablet

First Posted Date: 2014-07-02

Last Posted Date: 2014-09-04

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 30

Registration Number: NCT02179931

Locations: 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Phase 3

Withdrawn

Conditions: Dravet Syndrome

Interventions: Drug: Clobazam
Drug: Placebo

First Posted Date: 2014-06-25

Last Posted Date: 2015-09-24

Lead Sponsor: H. Lundbeck A/S

Registration Number: NCT02174094

Locations: 🇺🇸
US003, Rochester, Minnesota, United States
🇺🇸
US006, Dallas,, Texas, United States
🇺🇸
US010, Los Angeles, California, United States

and more 6 locations

Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lu AE58054 30 mg
Drug: Lu AE58054 30 mg + itraconazole 200 mg
Drug: Itraconazole

First Posted Date: 2014-04-24

Last Posted Date: 2014-06-19

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 20

Registration Number: NCT02122692

Locations: 🇫🇷
FR801, Rennes, France

Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women

Phase 1

Completed

Conditions: Healthy Women

Interventions: Drug: Encapsulated vortioxetine IR tablet, 20 mg
Drug: Vortioxetine MR capsule 20 mg (pH 5.5)
Drug: Vortioxetine MR capsule 20 mg (pH 7.0)
Drug: Vortioxetine MR capsule 20 mg (pH 6.0)

First Posted Date: 2014-04-14

Last Posted Date: 2014-11-13

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 40

Registration Number: NCT02112903

Locations: 🇬🇧
GB801, London, United Kingdom

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

Phase 1

Completed

Conditions: Healthy Men

First Posted Date: 2014-03-20

Last Posted Date: 2014-09-23

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 12

Registration Number: NCT02093169

Locations: 🇬🇧
GB801, London, United Kingdom

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Idalopirdine 60 mg

First Posted Date: 2014-03-05

Last Posted Date: 2018-08-10

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 1463

Registration Number: NCT02079246

Locations: 🇺🇸
US346, Costa Mesa, California, United States
🇺🇸
US310, Saint Paul, Minnesota, United States
🇺🇸
US024, Little Rock, Arkansas, United States

and more 255 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy